During the past decade, Yeungnam University Medical Center conducted 147 clinical trials. In the 10-year time frame, 147 clinical trials started and 49 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 50 clinical trials started and 34 clinical trials were completed. i.e. 68% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Yeungnam University Medical Center" #1 sponsor was "Hoffmann-La Roche" with 13 trials, followed by "Yeungnam University College of Medicine" with 13 trials sponsored, "Takeda" with 12 trials sponsored, "Celgene" with 10 trials sponsored and "Boehringer Ingelheim" with 10 trials sponsored. Other sponsors include 138 different institutions and companies that sponsored additional 87 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Yeungnam University Medical Center" #1 collaborator was "CardioVascular Research Foundation, Korea" with 12 trials as a collaborator, "Medtronic" with 4 trials as a collaborator, "Gilead Sciences" with 3 trials as a collaborator, "Korean Cancer Study Group" with 3 trials as a collaborator and "Ministry of Health & Welfare, Korea" with 3 trials as a collaborator. Other collaborators include 66 different institutions and companies that were collaborators in the rest 65 trials.

According to Clinical.Site data, the most researched conditions in "Yeungnam University Medical Center" are "Ulcerative Colitis" (16 trials), "Crohn's Disease" (12 trials), "Coronary Artery Disease" (11 trials), "Crohn Disease" (11 trials) and "Colitis, Ulcerative" (10 trials). Many other conditions were trialed in "Yeungnam University Medical Center" in a lesser frequency.

Most popular intervention types in "Yeungnam University Medical Center" are "Drug" (140 trials), "Device" (21 trials), "Other" (15 trials), "Procedure" (12 trials) and "Biological" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (36 trials), "Sham Procedure" (6 trials), "Etrolizumab" (4 trials), "Faricimab" (4 trials) and "Filgotinib" (4 trials). Other intervention names were less common.

The vast majority of trials in "Yeungnam University Medical Center" are 195 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are 55 active trials in "Yeungnam University Medical Center". 1 are not yet recruiting, 29 are recruiting, 24 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 102 completed trials in Yeungnam University Medical Center, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Yeungnam University Medical Center, 4 "Phase 1" clinical trials were conducted, 34 "Phase 2" clinical trials and 72 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 25 trials, and there were also 24 trials that are defined as “Not Applicable".